Brian Spencer

Assistant Professor Of Research Physiology and Neuroscience

Is this your profile? Click to edit

Publications

Systemic delivery of anti-sense oligonucleotide targeting α-synuclein for treatment in a mouse model of multiple system atrophy. Front Aging Neurosci. 2026; 18:1807721.. View in PubMed
Peptide-mediated delivery of an α-synuclein-targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy model. Drug Metab Dispos. 2026 06; 54(6):100304.. View in PubMed
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep. 2026 Mar 24; 45(3):117175.. View in PubMed
Systemic delivery of anti-sense oligonucleotide targeting a-synuclein for the treatment of multiple system atrophy. Res Sq. 2025 Nov 07.. View in PubMed
A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. NPJ Parkinsons Dis. 2025 Aug 22; 11(1):254.. View in PubMed
A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson’s disease. Alzheimers Dement (N Y). 2025 Apr-Jun; 11(2):e70117.. View in PubMed
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep. 2025 Jun 24; 44(6):115887.. View in PubMed
Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology. Neurobiol Dis. 2025 07; 211:106942.. View in PubMed